This technique of elimination of toxic substances is effective for poisoning with lead, mercury and other heavy metals. For other diseases, the proof is still missing.
As a result of poisoning by heavy metals such as lead or mercury, chelation has proved successful. It is a detoxification technique where an organic substance (the chelating agent) binds to ionized (i.e. electrically charged) minerals or metals such as iron, calcium, lead , the copper. As the resulting product is stable, nontoxic and soluble, it can easily be removed in the urine.
If heavy metals are concerned, to praise its merits to get rid of all the toxic pollution that accumulates in our bodies, there is a step that the health authorities refuse to cross. Likewise, concerning the supposed benefits of chelation on our arteries and, consequently, on all kinds of cardiovascular diseases: no effect of this kind could be rigorously demonstrated. It’s not better for autism. But it is however a track now followed for the treatment of neurodegenerative diseases.
Tested in many studies for lead or mercury poisoning, the effectiveness of chelation varies according to the protocols and the dosages. Its use nevertheless has the approval of health authorities for the specific purpose of heavy metal poisoning. A problem far from being trivial, given the neurological damage produced by that related to lead in young children, in particular.
But in terms of ridding our bodies of metals at lower doses than those observed during poisoning, there is not enough scientific evidence. We do not have more for vascular diseases. To fight against the formation of deposits in the arteries, some therapists placed their hopes on a chelating agent called EDTA suppositories, supposed to trap the calcium ions. But after double-blind clinical trials, no significant results could be observed. More seriously, if it really traps calcium ions, EDTA can at the same time induce more or less serious side effects (kidney problems, respiratory …). It is because of these risks that US health authorities have decided to discontinue two EDTA chelation clinical trials, one on heart disease.